Goldman Sachs Reinstates Dynavax Technologies (DVAX) at Buy

Get Alerts DVAX Hot Sheet
Rating Summary:
10 Buy, 1 Hold, 0 Sell
Rating Trend:

Today's Overall Ratings:
Up: 5 | Down: 15 | New: 12
Join SI Premium – FREE
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Goldman Sachs analyst Madhu Kumar reinstates coverage on Dynavax Technologies (NASDAQ: DVAX) with a Buy rating and a price target of $38.00.
The analyst commented, "While we are long-term bullish on the opportunity for hepatitis B virus (HBV) vaccine Heplisav-B to prove best-in-class in that space, with the recent CDC ACIP positive recommendation for universal HBV vaccination likely over time to expand the TAM, we see near-term value creation from the company's multiple COVID-19 vaccine partnerships for its adjuvant CpG 1018. In particular, we would highlight the SCB-2019 program with Clover Biopharma as an under-appreciated COVID-19 vaccine, given its broad capacity for protection and a potential best-in-class tolerability profile, leaving open a substantial opportunity for both ROW pandemic and booster endemic uptake."
For an analyst ratings summary and ratings history on Dynavax Technologies click here. For more ratings news on Dynavax Technologies click here.
Shares of Dynavax Technologies closed at $13.40 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Foot Locker Erupts 25% After Earnings, Earns Analyst Upgrades as New CEO is a 'Huge Positive'
- Stifel Starts MasterCraft Boat Holdings (MCFT) at Buy
- UPDATE: CLSA Upgrades LexinFintech Holdings (ADR) (LX) to Underperform (4)
Create E-mail Alert Related Categories
Analyst Comments, Hot New Coverage, New CoverageRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!